SG170073A1 - Long term treatment of hiv infection - Google Patents

Long term treatment of hiv infection

Info

Publication number
SG170073A1
SG170073A1 SG201101585-6A SG2011015856A SG170073A1 SG 170073 A1 SG170073 A1 SG 170073A1 SG 2011015856 A SG2011015856 A SG 2011015856A SG 170073 A1 SG170073 A1 SG 170073A1
Authority
SG
Singapore
Prior art keywords
long term
hiv infection
term treatment
formulation
treatment
Prior art date
Application number
SG201101585-6A
Other languages
English (en)
Inventor
Lieven Elvire Colette Baert
Guenter Kraus
Aet Klooster Gerben Albert Eleutherius Van
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36446113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG170073(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of SG170073A1 publication Critical patent/SG170073A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG201101585-6A 2006-01-20 2007-01-19 Long term treatment of hiv infection SG170073A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06100677 2006-01-20

Publications (1)

Publication Number Publication Date
SG170073A1 true SG170073A1 (en) 2011-04-29

Family

ID=36446113

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201101585-6A SG170073A1 (en) 2006-01-20 2007-01-19 Long term treatment of hiv infection

Country Status (28)

Country Link
US (3) US10953009B2 (es)
EP (1) EP1981506B3 (es)
JP (2) JP5754005B2 (es)
KR (2) KR101562943B1 (es)
CN (2) CN101370504A (es)
AP (1) AP2936A (es)
AR (1) AR059097A1 (es)
AU (1) AU2007206901B2 (es)
BR (1) BRPI0707179A2 (es)
CA (1) CA2636436C (es)
CY (1) CY1114089T1 (es)
DK (1) DK1981506T6 (es)
EA (1) EA014914B1 (es)
ES (1) ES2414982T7 (es)
HK (1) HK1125828A1 (es)
HR (1) HRP20130544T4 (es)
IL (1) IL192132A (es)
ME (1) ME01617B (es)
MY (1) MY150717A (es)
NZ (1) NZ569347A (es)
PL (1) PL1981506T6 (es)
PT (1) PT1981506E (es)
RS (1) RS52821B2 (es)
SG (1) SG170073A1 (es)
SI (1) SI1981506T1 (es)
TW (1) TWI458483B (es)
UA (1) UA96436C2 (es)
WO (1) WO2007082922A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
CL2007001847A1 (es) 2006-06-23 2008-02-08 Tibotec Pharm Ltd Composicion farmaceutica intramuscular o subcutanea que comprende tmc278 (rilpivirina); proceso para preparar la composicion; y uso para el tratamiento o prevencion de infeccion por vih.
AU2014200819B2 (en) * 2006-06-23 2016-05-26 Janssen Sciences Ireland Uc Aqueous suspensions of TMC278
AU2016219555B2 (en) * 2006-06-23 2017-08-10 Janssen Sciences Ireland Uc Aqueous suspensions of TMC278
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
MY160360A (en) * 2008-12-24 2017-02-28 Janssen Sciences Ireland Uc Implantable devices for treating hiv
MX2012003424A (es) * 2009-09-22 2012-05-08 Tibotec Pharm Ltd Tratamiento y prevencion de infeccion por el virus de inmunodeficiencia humana.
CA2784530C (en) 2009-12-21 2018-05-22 Janssen R&D Ireland Degradable removable implant for the sustained release of an active compound
KR20170078868A (ko) 2010-01-27 2017-07-07 비이브 헬쓰케어 컴퍼니 항바이러스 치료
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
US9266824B2 (en) 2014-01-13 2016-02-23 Warsaw Orthopedic, Inc. Methods and compositions for making an amino acid triisocyanate
SG11201804037XA (en) * 2015-11-16 2018-06-28 Evonik Roehm Gmbh Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide)
US20190163877A1 (en) * 2017-11-27 2019-05-30 International Business Machines Corporation Decision support for effective long-term drug therapy
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US6568805B1 (en) * 2001-11-26 2003-05-27 Dan L. Dietz Trust Magnetic buckle for eyeglasses
AU2003210659A1 (en) * 2002-01-24 2003-09-02 Sangstat Medical Corporation Combination therapy for treatment of hiv infection
EP1632232B3 (en) * 2004-09-02 2022-03-30 Janssen Pharmaceutica NV Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
PL1632232T6 (pl) * 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防

Also Published As

Publication number Publication date
IL192132A0 (en) 2009-08-03
AP2008004535A0 (en) 2008-08-31
BRPI0707179A2 (pt) 2011-04-26
DK1981506T6 (da) 2021-06-14
ME01617B (me) 2014-09-20
JP5754005B2 (ja) 2015-07-22
EA200870183A1 (ru) 2009-12-30
UA96436C2 (ru) 2011-11-10
KR101562943B1 (ko) 2015-10-23
KR20080085194A (ko) 2008-09-23
AP2936A (en) 2014-07-31
JP5836983B2 (ja) 2015-12-24
DK1981506T3 (da) 2013-06-24
PT1981506E (pt) 2013-06-25
CY1114089T1 (el) 2016-07-27
TWI458483B (zh) 2014-11-01
PL1981506T3 (pl) 2013-08-30
CA2636436C (en) 2014-04-01
WO2007082922A8 (en) 2008-01-03
SI1981506T1 (sl) 2013-08-30
CN101370504A (zh) 2009-02-18
ES2414982T3 (es) 2013-07-23
WO2007082922A3 (en) 2007-09-20
EP1981506B1 (en) 2013-03-27
CN103877091A (zh) 2014-06-25
KR101501475B1 (ko) 2015-03-19
AR059097A1 (es) 2008-03-12
US20110275654A1 (en) 2011-11-10
MY150717A (en) 2014-02-28
AU2007206901A1 (en) 2007-07-26
JP2013100338A (ja) 2013-05-23
HRP20130544T4 (hr) 2021-08-20
WO2007082922A2 (en) 2007-07-26
EP1981506A2 (en) 2008-10-22
TW200806295A (en) 2008-02-01
NZ569347A (en) 2011-07-29
KR20140141699A (ko) 2014-12-10
ES2414982T7 (es) 2021-11-05
JP2009526758A (ja) 2009-07-23
CA2636436A1 (en) 2007-07-26
RS52821B (en) 2013-10-31
RS52821B2 (sr) 2021-07-30
HK1125828A1 (en) 2009-08-21
US20240226099A1 (en) 2024-07-11
EP1981506B3 (en) 2021-06-09
PL1981506T6 (pl) 2021-07-12
IL192132A (en) 2014-05-28
US10953009B2 (en) 2021-03-23
AU2007206901B2 (en) 2013-01-31
US20210177843A1 (en) 2021-06-17
EA014914B1 (ru) 2011-02-28
HRP20130544T1 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
TW200806295A (en) Long term treatment of HIV infection
JOP20200160A1 (ar) محاليل معلقة مائية للمركبات المسمى تي ام سي 278
MX2009006764A (es) Pirimidinonas biciclicas y usos de la misma.
UA90124C2 (ru) Способ профилактики вич-инфекции с помощью тмс278
RS51965B (en) USE 2-6- (3-AMINO-PIPERIDIN-1-IL) -3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-ILMETHYL-4-FLUORO-BENZONITRIL FOR THE TREATMENT OF DIABETES, Cancers, autoimmune disorders and HIV infections
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
NZ627824A (en) Antiviral combinations involving (4r,12as)-n-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2hpyrido[1’,2’:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
MX2013005478A (es) Compuestos heterociclicos condensados antivirales.
MX2012007410A (es) Compuestos antivirales novedosos.
NZ616806A (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
WO2005089738A3 (en) Use and administration of bacterial efflux pump inhibitors
UA96449C2 (en) Stable laquinimod preparations
NZ582089A (en) Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir
TW200510425A (en) Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
NZ595313A (en) The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX336657B (es) Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2.
MX2012006297A (es) Uso topico hidroxitirosol y derivados para la prevencion de la infeccion por vih.
BRPI0920605A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste.
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
WO2012024363A3 (en) Compounds and methods for the treatment or prevention of flaviviridae viral infections
WO2007144889A3 (en) Treatment of neurofibromatosis
NZ542305A (en) Treatment of proliferative diseases with an epothilone derivative and radiation
WO2010033219A3 (en) Protease inhibitors having enhanced features
GB0229022D0 (en) Organic Compounds